Key clinical point: Relative to azithromycin for nonsevere bronchiectasis in children, amoxicillin/clavulanate was more effective.
Major finding: Relative to placebo, the risk ratio for exacerbation resolution was higher for amoxicillin/clavulanate (risk ratio, 1.5) than azithromycin (RR, 1.4)
Data Source: Double-blind, multicenter, placebo-controlled trial.
Disclosures: Dr. Goyal reported no potential conflicts of interest.
Goyal V et al. Lancet Respir Med. 2019;7:791-801.